Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Botulinum Toxin

  • Author: Divakara Kedlaya, MBBS; Chief Editor: Elizabeth A Moberg-Wolff, MD  more...
 
Updated: Jun 02, 2016
 

Overview

Botulinum toxin (abbreviated either as BTX or BoNT) is produced by Clostridium botulinum, a gram-positive anaerobic bacterium.[1] The clinical syndrome of botulism can occur following ingestion of contaminated food, from colonization of the infant gastrointestinal tract, or from a wound infection.

BoNT is broken into 7 neurotoxins (labeled as types A, B, C [C1, C2], D, E, F, and G), which are antigenically and serologically distinct but structurally similar. Human botulism is caused mainly by types A, B, E, and (rarely) F. Types C and D cause toxicity only in animals.

The various botulinum toxins possess individual potencies, and care is required to assure proper use and avoid medication errors. Recent changes to the established drug names by the FDA were intended to reinforce these differences and prevent medication errors. The products and their approved indications include the following:

  • OnabotulinumtoxinA (Botox®, Botox Cosmetic®)
    • Botox® - Cervical dystonia, severe primary axillary hyperhidrosis, strabismus, blepharospasm, neurogenic detrusor overactivity, chronic migraine, upper limb spasticity
    • Botox Cosmetic® - Moderate to severe glabellar lines, moderate to severe lateral canthal lines, known as crow’s feet
  • AbobotulinumtoxinA (Dysport®) - Upper limb spasticity, cervical dystonia, moderate to severe glabellar lines.
  • IncobotulinumtoxinA (Xeomin®) - Upper limb spasticity, cervical dystonia, blepharospasm, moderate to severe glabellar lines.
  • RimabotulinumtoxinB (Myobloc®) - Cervical dystonia

The BoNT molecule is synthesized as a single chain (150 kD) and then cleaved to form the dichain molecule with a disulfide bridge (see image below).

Botulinum toxin structure (schematic diagram). Botulinum toxin structure (schematic diagram).

The light chain (~50 kD - amino acids 1-448) acts as a zinc (Zn2+) endopeptidase similar to tetanus toxin with proteolytic activity located at the N-terminal end (see image below). The heavy chain (~100 kD - amino acids 449-1280) provides cholinergic specificity and is responsible for binding the toxin to presynaptic receptors; it also promotes light-chain translocation across the endosomal membrane.

Proteolytic activity is located at the N-terminal Proteolytic activity is located at the N-terminal end of the light chain of botulinum toxin type A.

For patient education resources, see the Procedures Center, as well as BOTOX® Injections.

Next

History

The German physician and poet Justinus Kerner (1786-1862) first developed the idea of a possible therapeutic use of botulinum toxin, which he called "sausage poison."[2]

  • In 1870, Muller (another German physician) coined the name botulism. The Latin form is botulus, which means sausage.
  • In 1895, Professor Emile Van Ermengem, of Belgium, first isolated the bacterium Clostridium botulinum.
  • In 1928, Dr. Herman Sommer, at the University of California, San Francisco, first isolated in purified form botulinum toxin type A (BoNT-A) as a stable acid precipitate.
  • In 1946, Dr. Edward J Schantz succeeded in purifying BoNT-A in crystalline form–cultured Clostridium botulinum and isolated the toxin.
  • In 1949, Dr. Burgen's ASV group discovered that botulinum toxin blocks neuromuscular transmission.
  • In the 1950s, Dr. Vernon Brooks discovered that when BoNT-A is injected into a hyperactive muscle, it blocks the release of acetylcholine from motor nerve endings.
  • In 1973, Dr. Alan B. Scott, of Smith-Kettlewell Eye Research Institute, used BoNT-A in monkey experiments; in 1980, he used BoNT-A for the first time in humans to treat strabismus.
  • In December 1989, BoNT-A (BOTOX®) was approved by the US Food and Drug Administration (US FDA) for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients aged younger than 12 years.
  • On December 21, 2000, BoNT-A received US FDA approval for treatment of cervical dystonia.
  • In 2001, the United Kingdom approved BOTOX®, synthesized by Allergan, for axillary hyperhidrosis (excessive sweating). Canada approved BOTOX® for axillary hyperhidrosis, focal muscle spasticity, and cosmetic treatment of wrinkles at the brow line.
  • On April 15, 2002, the US FDA announced the approval of BOTOX® Cosmetic to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines). On July 21, 2011, the US FDA approved incobotulinumtoxinA (Xeomin) for temporary improvement in the appearance of moderate-to-severe glabellar lines, or frown lines between the eyebrows, in adult patients.
  • In July 2004, the US FDA approved BOTOX® to treat severe underarm sweating, known as primary axillary hyperhidrosis that cannot be managed by topical agents, such as prescription antiperspirants.
  • The acceptance of BoNT-A use for the treatment of different chronic pain disorders is growing. However, it has not been approved by the US FDA for any chronic pain conditions except for chronic migraine.
  • The clinical use of BoNT-B has been studied, and several products currently are available commercially (eg, MyoBloc, in the United States; NeuroBloc, in Europe). MyoBloc was approved by the US FDA on December 8, 2000, for treatment of cervical dystonia, to reduce the severity of abnormal head position and neck pain.
  • Use of BoNT-F also is under investigation in patients who have become immunologically resistant to serotypes A and B.
  • On April 29, 2009, abobotulinumtoxinA (Dysport) was approved by the US FDA for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients.
  • On March 9, 2010, the US FDA approved onabotulinumtoxinA (BOTOX®) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults with stroke, traumatic brain injury, or the progression of multiple sclerosis.
  • On August 2, 2010, the US FDA announced the approval of incobotulinumtoxinA (Xeomin®) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and for blepharospasm in adults previously treated with BOTOX®.
  • On October 15, 2010, the US FDA approved onabotulinumtoxinA (BOTOX®) injection to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.
  • On August 24, 2011, the US FDA approved onabotulinumtoxinA (BOTOX®) injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
  • On September 11, 2013, the US FDA approved onabotulinumtoxinA (BOTOX®) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet. This is the only FDA-approved drug treatment option for lateral canthal lines.
  • On July 16, 2015, the US FDA approved Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors.
  • On December 23, 2015, the US FDA approved Xeomin® (incobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients.
Previous
Next

Mechanism of Action

Botulinum toxin acts by binding presynaptically to high-affinity recognition sites on the cholinergic nerve terminals and decreasing the release of acetylcholine, causing a neuromuscular blocking effect. This mechanism laid the foundation for the development of the toxin as a therapeutic tool.

Recovery occurs through proximal axonal sprouting and muscle re-innervation by formation of a new neuromuscular junction. De Paiva and colleagues suggest that eventually the original neuromuscular junction regenerates.[3]

  • BoNT-A and BoNT-E cleave synaptosome-associated protein (SNAP-25), a presynaptic membrane protein required for fusion of neurotransmitter-containing vesicles. [4]
  • BoNT-B, BoNT-D, and BoNT-F cleave a vesicle-associated membrane protein (VAMP), also known as synaptobrevin.
  • BoNT-C acts by cleaving syntaxin, a target membrane protein.

Table 1. Botulinum Toxin Types, Target Sites, Discoverers, and Year Discovered (Open Table in a new window)

Type Target Discoverer Year
A SNAP-25 Landman 1904
B VAMP Ermengem 1897
C1 Syntaxin Bengston and Seldon 1922
D VAMP Robinson 1929
E SNAP-25 Gunnison 1936
F VAMP Moller and Scheibel 1960
G VAMP Gimenez and Ciccarelli 1970

 

Previous
Next

Preparations

The different preparations of BoNT-A, onabotulinumtoxinA (BOTOX®; Allergan; Irvine, Calif), abobotulinumtoxinA (Dysport®; Ipsen; Paris, France), incobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals, Frankfurt, Germany), CS-BOT (Chiba Serum Institute; Chiba, Japan), and Chinese BTX-A (Prosigne ®; Lanzhou Biological Products Institute, China) differ in potency.[5]

  • BoNT-A is prepared by laboratory fermentation of C botulinum cultures. Crude botulinum toxin is a protein with a molecular weight of about 190,000 Daltons. After purification, the toxin is diluted with human serum albumin, bottled in vials, lyophilized (freeze-dried), and sealed.
  • Each freeze-dried vial containing 100 units (U) of BoNT-A is reconstituted with preservative-free normal saline (1-5 mL) just before use. The manufacturer recommends that the toxin be used within 4 hours of reconstitution.
  • The potency of BoNT-A is measured in mouse units (MU). One MU of BoNT-A is equivalent to the amount of toxin that kills 50% of a group of 20 g Swiss-Webster mice within 3 days of intraperitoneal injection (LD50).
  • According to one report, 1 nanogram of toxin contains approximately 20 U of BOTOX® (ie, 1 U of BOTOX® is equal to approximately 0.05 nanogram of the toxin).
  • According to another report comparing the 3 different preparations of BoNT-A, 1 nanogram of Dysport contains approximately 40 MU, whereas 1 nanogram of the BOTOX® contains approximately 4 MU, and 1 nanogram of CS-BOT contains approximately 15.2 MU.
  • Median paralysis unit (MPU) is thought to be a more pharmacologically relevant unit of biologic activity. Comparison of the potency ratio based on the MPU values for Dysport and BOTOX ® revealed a 2.44-fold difference in potency between these formulations. [6]
  • LD50 of BoNT-A for a 70-kg adult male has been calculated to be 2500-3000 U (35-40 U/kg).
  • Minimum lethal dose of BoNT-B in monkeys is 2400 U/kg.
  • Clinically, 1 U of BoNT-A (BOTOX ®) is approximately equivalent to 3 U of Dysport ®. [7]
  • Studies of Xeomin ® and Prosigne ® use unit dosing comparable (1:1) with BOTOX ®. [8, 9]
  • An animal study that found that Xeomin® contains the highest specific neurotoxin activity, followed by Dysport®, with BOTOX ® having the lowest specific activity. [10]
  • Standardization efforts are underway using measurements of the toxin's pharmacologically relevant actions (eg, median paralysis unit).
  • BOTOX® vials contain sodium chloride (0.9 mg) and human albumin (0.5 mg), and the protein load is 5 ng/100 units; Prosigne® vials contain porcine gelatin (5 mg), dextran (25 mg), and sucrose (25 mg), and the protein load is 4-5 ng/100 units of BoNT-A. [11] BOTOX® is thought to be about 1.5 times more potent than Prosigne®.
  • BoNT-B is marketed in the United States as RimaBotulinumB (MyoBloc®). This preparation is a ready-to-use solution that does not require reconstitution; it is available in 3 vial sizes (ie, 2500 U, 5000 U, and 10,000 U) and is stable for up to 21 months in refrigerator storage.
Previous
Next

Therapeutic Uses

Therapeutic uses of botulinum toxin injection [12]  [13]

Previous
Next

Botulinum Toxin Use in Dystonia

Use of BoNT-A in different types of focal dystonias has been well studied and has proven to be very effective. Botulinum toxin injection is the treatment of choice for cervical dystonia (spasmodic torticollis).[14, 15, 87] . A Cochrane review concluded that a single injection of BoNT-B was effective and safe for treating cervical dystonia.[88] This injection benefits the highest percentage of patients in the shortest time and has been proven effective in many double-blind, placebo-controlled trials.

BoNT has fewer side effects than do other pharmacologic treatments. The efficacy and safety of BoNT injections for the treatment of certain movement disorders, including blepharospasm, hemifacial spasm, oromandibular dystonia, cervical dystonia, focal limb dystonias, laryngeal dystonia, tics, and essential tremor is ongoing.[89]

In a double-blind, placebo-controlled trial by Greene and colleagues, 55 patients who previously had failed to find relief in 2 trials of medication received either BoNT or placebo in a double-blinded fashion and were tracked for 12 weeks.[90] Four weeks of open phase then followed when all patients received BoNT. By 6 weeks, 61% of patients showed improvement in head posture, and 39.5% reported reduction of pain. Both measures significantly improved (P < .05) compared to controls. During the open phase, patients who previously received placebo exhibited a similar response. Overall, 74% of patients improved by the end of the study.

A study by Brans and colleagues showed that in 64 patients with cervical dystonia, 84% reported long-term benefits in terms of impairment, disability, handicap, and quality of life (QOL).[91] Mezaki et all described their experience with a Japanese type A toxin for the treatment of cervical and axial dystonias.[92] Injections were given repeatedly at intervals of 28-30 days to carefully chosen muscles with increased activities, with a maximum dose per session of 300 units. The maximum improvements in subjective and objective ratings were obtained only after repeated injections.

Procedure

Treatment dosages of BoNT-A in the United States have been reported to range from 100-300 U per patient. In a double-blind, placebo-controlled study, Poewe and colleagues demonstrated that magnitude and duration of improvement were greatest after injections of 1000 U of Dysport, but the injections caused significantly more adverse effects.[93] The researchers recommended a lower starting dose of 500 U of Dysport (1 U of BoNT-A = 3 U of Dysport). One hundred U of toxin per mL of preservative-free normal saline are commonly used.

Injections are performed with a Teflon-coated, 24-gauge needle connected to an electromyographic (EMG) machine. Those muscles with highest clinical and EMG activity are injected. Usually, 2-4 separate muscles are injected in 1 session and, in larger muscles, 2-4 sites per muscle are injected.

No general consensus exists among users of BoNT regarding the need for EMG guidance while injecting the compound for cervical dystonia. EMG guidance, however, is helpful, particularly in obese patients whose neck muscles cannot adequately be palpated.

Identifying the specific muscles involved in cervical dystonia prior to the injection is important. Those most commonly injected are the sternocleidomastoid, trapezius, splenius capitis, and levator scapulae muscles. An EMG study of 100 patients found that 2 or 3 muscles commonly are abnormal. Eighty-nine percent of patients with rotating torticollis had involvement of the ipsilateral splenius capitis and contralateral sternocleidomastoid with or without the additional involvement of the contralateral splenius capitis. Patients with laterocollis had ipsilateral sternocleidomastoid, splenius capitis, and trapezius involvement, while retrocollis was produced by bilateral splenius capitis activity.

Beneficial effect from toxin injection usually is apparent in 7-10 days. Maximum response from the toxin is reached in approximately 4-6 weeks and lasts for an average of 12 weeks. Injections usually are repeated every 3-4 months.

Complications

Neck weakness, dysphagia, and local pain at the injection site are the most commonly reported side effects. Other adverse effects (eg, local hematoma, generalized fatigue, lethargy, dizziness, dry mouth, dysphonia, flulike syndrome, pain in neighboring muscles) also have been reported.

Most studies have reported side effects in 20-30% of patients per treatment cycle. The incidence of adverse effects varies based on the dosage used (ie, the higher the dose, the more frequent the adverse effects); however, Jankovic and Schwartz reported that incidence of complications was not related to the total dose of BoNT used.[94] Women and patients who received injections into the sternocleidomastoid muscles had significantly higher rates of complications.

Dysphagia has been the most prevalent significant complication and most probably is related to diffusion of the toxin into nearby pharyngeal muscles. In the study by Comella and colleagues, 33% of patients receiving their first dose of botulinum toxin experienced dysphagia.[95] This complication most commonly occurs with injections of the sternocleidomastoid and can be reduced significantly when the dose of toxin administered is 100 U or less.

Previous
Next

Botulinum Toxin Use in Spasticity

Spasticity is defined as a velocity-dependent increase in muscle tone. Intramuscular injections of BoNT have been studied and found to be useful in the treatment of spasticity in multiple sclerosis (MS), cerebral palsy (CP), stroke, traumatic brain injury (TBI), and spinal cord injury (SCI). Different studies have shown the effectiveness of BoNT-A injection in the management of spasticity.[23]

Table 2. Studies of Botulinum Toxin in the Treatment of Spasticity in Different Disorders (Open Table in a new window)

Clinical Diagnosis Author Study Design
Multiple Sclerosis Benecke



Borg-Stein et al[96]



Snow et al[97]



Hyman et al[98]



Open-label



Open-label



Double-blind, placebo-controlled, randomized, crossover



Double-blind, placebo-controlled, randomized, dose-ranging



Spinal Cord Injury Bohlega et al



Takenaga et al



Open-label



Open-label



Cerebral Palsy Koman et al[99] Koman et al[100]



Cosgrove et al[101]



Chutorian and Root



Chutorian, Root, and the BTA study group



Corry et al[102]



Fehlings et al[103]



Wissel et al[104]



Baker et al[105]



Edwards et al[106]



Open-label



Double-blind, placebo-controlled



Open-label



Open-label



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled



Single-blind, randomized, controlled



Double-blind, randomized, placebo-controlled



Double-blind, randomized, placebo-controlled



Double-blind, randomized, placebo-controlled



Stroke Das and Park Memin et al



Grazko et al



Dengler et al



Jabbari et al



Simpson et al



Bhaktha et al[107]



Smith et al[108]



Childers et al[109]



Pittock et al[110]



Brashear et al[111]



Bakheit et al[112]



Open-label



Open-label



Double-blind, placebo-controlled, crossover



Open-label



Double-blind, placebo-controlled, crossover



Double-blind, placebo-controlled



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Traumatic Brain Injury Yablon et al[113]



Pavesi et al[114]



Open-label



Open-label



 

Previous
Next

Pain Management

Use of BoNT-A in the management of different pain disorders is being studied.[115] At this time, indications for the use of BoNT in managing muscle pain disorders still are controversial. The exact mechanism of action behind BoNT's analgesic effect is not known; however, a study by Purkiss and colleagues showed that BoNT inhibits calcium-dependent release of substance P in embryonic dorsal root ganglia.[116] Hence, BoNT may, by blocking the release of substance P, produce an analgesic effect through peripheral inhibition of C and A delta fibers. Based on the research with animal models, BoNT-A in peripheral nociceptive neurons plays a direct role in its peripheral analgesic effect and an indirect role in its central analgesic effect because of retrograde transport.[117]

In a double-blind, randomized, placebo-controlled study, Foster and colleagues showed the efficacy of 200 U of BoNT-A injection, using 40 U per site at 5 lumbar paravertebral levels on the side of maximum discomfort, in chronic low back pain patients.[118]

A Cochrane review regarding the use of BoNT-A injection for chronic low back pain has concluded evidence that BoNT injections improved pain, function, or both better than saline injections was limited, as was evidence this was better than acupuncture or steroid injections.[119] They recommend further high quality randomized controlled studies.

BoNT-A injection has also been studied for chronic neck pain, cervicogenic headache, and whiplash-associated neck pain; however, a Cochrane review and systematic review and meta-analysis by Langevin et al concluded that current evidence fails to confirm either a clinically important or a statistically significant benefit of BoNT-A injection for whiplash-associated neck pain and chronic neck pain associated with or without cervicogenic headache.[120, 121]

BoNT-A has been studied to treat different neuropathic pain disorders such as postherpetic neuralgia,[122] trigeminal neuralgia,[123, 124] and diabetic peripheral neuropathic pain,[125] and has shown to be effective in managing pain in these conditions.

Different studies on the use of BoNT in the management of different pain disorders are listed in Table 3.

Table 3. Studies on the Use of Botulinum Toxin in Pain Management (Open Table in a new window)

Author(s) (Year) Clinical Condition Study Type N Results
Zwart et al (1994)[126] Tension headache Open-label 6 Unilateral temporal injection not effective
Sherman et al (1995)[127] Chronic pancreatitis Open-label 7 Not effective
Paulson et al (1996)[128] Fibromyalgia Randomized, controlled 5 Not effective
Wheeler et al (1998)[129] Myofascial pain[130] Randomized, double-blind, controlled 33 No significant difference, second injection effective?
Wheeler (1998)[131] Tension headache Open-label 4 Effective in 4 patients
Schulte-Mattler et al (1999)[132] Tension headache Open-label 9 Effective in 8 of 9 patients
Freund et al (1999)[133] Temporomandibular disorders Open-label 15 Effective
Freund et al (2000)[134] Temporomandibular disorders Open-label 46 Effective
Silberstein et al (2000)[135] Migraine headache Double-blind, vehicle-controlled 123 Effective prophylaxis
Rollnik et al (2000)[136] Tension headache Double-blind, placebo-controlled 21 Not effective
Freund et al (2000)[137] Cervicogenic Headache Randomized, double-blind, placebo-controlled 26 Effective
Freund et al (2000)[138] Whiplash associated with neck pain Randomized, double-blind, placebo-controlled 26 Effective
Barwood et al (2000)[139] Severe postoperative pain and spasm in cerebral palsy Randomized, double-blind, placebo-controlled 16 Effective prophylaxis
Porta (2000)[140] Chronic myofascial pain syndrome Randomized, controlled, comparative 40 BOTOX® better than methylprednisolone

 

For more information, see Medscape Reference article Botulinum Toxin in Pain Management.

Previous
Next

Adverse Events

Adverse events due to therapeutic and cosmetic injection of BoNT reported to the FDA include respiratory problems, dysphagia, seizure, flulike syndrome, facial and other muscle weakness, ptosis, and skin and injection site reactions.[141] Of the 406 reports related to therapeutic use, 217 met the FDA's definition of serious, with 28 deaths and 17 seizures reported. Clinical characteristics submitted to the FDA for therapeutic cases differed from those of cosmetic BoNT cases, which were usually less serious. Most of the adverse effects linked to local tissue diffusion of BoNT. Careful attention to drug dose, dilution, handling, storage, and site of injection are required for optimal treatment outcome and to minimize adverse effects.

Previous
 
Contributor Information and Disclosures
Author

Divakara Kedlaya, MBBS Clinical Associate Professor, Department of Physical Medicine and Rehabilitation, Loma Linda University School of Medicine; Medical Director, Physical Medicine and Rehabilitation and Pain Management, St Mary Corwin Medical Center

Divakara Kedlaya, MBBS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Colorado Medical Society, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michael T Andary, MD, MS Professor, Residency Program Director, Department of Physical Medicine and Rehabilitation, Michigan State University College of Osteopathic Medicine

Michael T Andary, MD, MS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, Association of Academic Physiatrists

Disclosure: Received honoraria from Allergan for speaking and teaching.

Chief Editor

Elizabeth A Moberg-Wolff, MD Medical Director, Pediatric Rehabilitation Medicine Associates

Elizabeth A Moberg-Wolff, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Acknowledgements

Martin K Childers, DO, PhD Professor, Department of Neurology, Wake Forest University School of Medicine; Professor, Rehabilitation Program, Institute for Regenerative Medicine, Wake Forest Baptist Medical Center

Martin K Childers, DO, PhD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Congress of Rehabilitation Medicine, American Osteopathic Association, Christian Medical & Dental Society, and Federation of American Societies for Experimental Biology

Disclosure: Allergan pharma Consulting fee Consulting

References
  1. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981 Sep. 33(3):155-88. [Medline].

  2. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999 Nov 10. 53(8):1850-3. [Medline].

  3. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999 Mar 16. 96(6):3200-5. [Medline]. [Full Text].

  4. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993 Sep 9. 365(6442):160-3. [Medline].

  5. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997. 6:S146-68. [Medline].

  6. Pearce LB, Borodic GE, Johnson EA, First ER, MacCallum R. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon. 1995 Feb. 33(2):217-27. [Medline].

  7. Wohlfarth K, Schwandt I, Wegner F, Jürgens T, Gelbrich G, Wagner A. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008 Dec. 255(12):1932-9. [Medline].

  8. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007 Jan-Feb. 30(1):39-42. [Medline].

  9. Wohlfarth K, Müller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol. 2007 Mar-Apr. 30(2):86-94. [Medline].

  10. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010. 10(2):67-73. [Medline]. [Full Text].

  11. Tang X, Wan X. Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J (Engl). 2000 Sep. 113(9):794-8. [Medline].

  12. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997. 6:S129-45. [Medline].

  13. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10. 86 (19):1818-26. [Medline].

  14. Dowson AJ, Kilminster SG, Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D. 2008. 9(3):147-58. [Medline].

  15. Tiple D, Strano S, Colosimo C, et al. Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A. J Neurol. 2008 Jun. 255(6):843-7. [Medline].

  16. Kedlaya D, Reynolds LW, Strum SR. Effective treatment of cervical dystonia with botulinum toxin: review. J Back & Musculoskeletal Rehab. 1999. 13:3-10.

  17. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997 Sep. 49(3):701-7. [Medline].

  18. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord. 1991. 6(2):145-50. [Medline].

  19. Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988. 50:583-91. [Medline].

  20. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991 Jun. 101(6 Pt 1):630-4. [Medline].

  21. Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle Nerve. 2016 Mar. 53 (3):415-21. [Medline].

  22. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015 Oct. 14 (10):992-1001. [Medline].

  23. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008 May. 89(5):799-806. [Medline].

  24. Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain. Stroke. 2011 May. 42(5):1371-9. [Medline].

  25. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil. 2005 Mar. 19(2):117-25. [Medline].

  26. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev. 2005 Jan 25. CD004899. [Medline].

  27. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12. 56(11):1523-8. [Medline].

  28. Rath JJ, Tavy DL, Wertenbroek AA, van Woerkom TC, de Bruijn SF. Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord. 2010 Aug. 16(7):478-81. [Medline].

  29. Liu HB, Fan JP, Lin SZ, Zhao SW, Lin Z. Botox transient treatment of tinnitus due to stapedius myoclonus: case report. Clin Neurol Neurosurg. 2011 Jan. 113(1):57-8. [Medline].

  30. Anis MM, Pollak N. Treatment of palatal myoclonus with botulinum toxin injection. Case Rep Otolaryngol. 2013. 2013:231505. [Medline]. [Full Text].

  31. Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010 Jan. 89(1):16-23. [Medline].

  32. Fietzek UM, Kossmehl P, Barthels A, Ebersbach G, Zynda B, Wissel J. Botulinum toxin B increases mouth opening in patients with spastic trismus. Eur J Neurol. 2009 Dec. 16(12):1299-304. [Medline].

  33. Farid M, Youssef T, Mahdy T, Omar W, Moneim HA, El Nakeeb A. Comparative study between botulinum toxin injection and partial division of puborectalis for treating anismus. Int J Colorectal Dis. 2009 Mar. 24(3):327-34. [Medline].

  34. Carruthers JD, Kennedy RA, Bagaric D. Botulinum vs adjustable suture surgery in the treatment of horizontal misalignment in adult patients lacking fusion. Arch Ophthalmol. 1990 Oct. 108(10):1432-5. [Medline].

  35. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981. 79:734-70. [Medline]. [Full Text].

  36. Zhang T, Adatia A, Zarin W, Moitri M, Vijenthira A, Chu R. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology. 2011 Feb. 19(1):21-34. [Medline].

  37. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R,. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006 Nov. 125(1-2):82-8. [Medline].

  38. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994 Oct. 59(1):65-9. [Medline].

  39. Straube A, Empl M, Ceballos-Baumann A, Tolle T, Stefenelli U, Pfaffenrath V. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol. 2008 Mar. 15(3):205-13. [Medline].

  40. Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache. 2009 May. 49(5):732-43. [Medline].

  41. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache. Curr Rev Pain. 2000. 4(1):31-5. [Medline].

  42. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun. 50(6):921-36. [Medline].

  43. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 Jul. 30(7):804-14. [Medline].

  44. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011 Jan. 51(1):21-32. [Medline].

  45. Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011 Oct 11. 77(15):1465-72. [Medline].

  46. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011 Aug. 12(4):427-33. [Medline].

  47. Kalichman L, Bannuru RR, Severin M, Harvey W. Injection of botulinum toxin for treatment of chronic lateral epicondylitis: systematic review and meta-analysis. Semin Arthritis Rheum. 2011 Jun. 40(6):532-8. [Medline].

  48. Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R. 2010 Apr. 2(4):268-76. [Medline].

  49. Singer BJ, Silbert PL, Song S, Dunne JW, Singer KP. Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomised placebo controlled crossover trial. Br J Sports Med. 2011 Jun. 45(8):640-5. [Medline].

  50. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May. 153(5):205-16. [Medline].

  51. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke. 2008 Jan. 39(1):126-31. [Medline].

  52. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008 Sep. 64(3):274-83. [Medline].

  53. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009 Apr 28. 72(17):1473-8. [Medline].

  54. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011. (12):CD005493. [Medline].

  55. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011 Oct. 60(4):742-50. [Medline].

  56. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011 Jun. 185(6):2229-35. [Medline].

  57. Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010 Dec. 184(6):2423-8. [Medline].

  58. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005 Dec. 76(12):1670-6. [Medline].

  59. Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord. 2011 May. 49(5):659-64. [Medline].

  60. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990 Jan. 71(1):24-6. [Medline].

  61. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil. 1998 Jun. 79(6):715-7. [Medline].

  62. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011 Sep. 186(3):965-70. [Medline].

  63. Kuo HC. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005 Apr. 65(4):670-4. [Medline].

  64. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003 Aug. 62(2):259-64; discussion 264-5. [Medline].

  65. Zhu Q, Liu J, Yang C. Clinical study on combined therapy of botulinum toxin injection and small balloon dilation in patients with esophageal achalasia. Dig Surg. 2009 Feb. 26(6):493-8. [Medline].

  66. Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut. 2000 May. 46(5):597-600. [Medline]. [Full Text].

  67. Patrus B, Nasr A, Langer JC, Gerstle JT. Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease. J Pediatr Surg. 2011 Jan. 46(1):184-7. [Medline].

  68. Wehrmann T, Schmitt TH, Arndt A, Lembcke B, Caspary WF, Seifert H. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther. 2000 Nov. 14(11):1469-77. [Medline].

  69. Wehrmann T, Seifert H, Seipp M, Lembcke B, Caspary WF. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy. 1998 Oct. 30(8):702-7. [Medline].

  70. Patti R, Arcara M, Bonventre S, Sammartano S, Sparacello M, Vitello G. Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids. Br J Surg. 2008 Nov. 95(11):1339-43. [Medline].

  71. Davies J, Duffy D, Boyt N, Aghahoseini A, Alexander D, Leveson S. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum. 2003 Aug. 46(8):1097-102. [Medline].

  72. Brisinda G, Cadeddu F, Brandara F, et al. Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy. Br J Surg. 2008 Jun. 95(6):774-8. [Medline].

  73. Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999 Jul 8. 341(2):65-9. [Medline].

  74. Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum. 2012 Feb. 41(4):599-603. [Medline].

  75. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994 Jul. 94(1):94-9. [Medline].

  76. Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg. 1999 Feb. 103(2):656-63; discussion 664-5. [Medline].

  77. Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999 Feb. 103(2):645-52; discussion 653-5. [Medline].

  78. Schnider P, Binder M, Kittler H, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol. 1999 Apr. 140(4):677-80. [Medline].

  79. Dulguerov P, Quinodoz D, Cosendai G, Piletta P, Lehmann W. Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg. 2000 Jun. 122(6):821-7. [Medline].

  80. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009 Feb. 39(2):137-43. [Medline].

  81. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg. 2009 Jan. 111(1):79-82. [Medline].

  82. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr. 256(4):563-7. [Medline].

  83. Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol. 2011 Jun. 53(6):559-64. [Medline].

  84. Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011 Jul. 26(7):838-43. [Medline].

  85. Yang TY, Jung YG, Kim YH, Jang TY. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg. 2008 Sep. 139(3):367-71. [Medline].

  86. Unal M, Sevim S, Dogu O, Vayisoglu Y, Kanik A. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol. 2003 Dec. 123(9):1060-3. [Medline].

  87. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S,. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15. 308(1-2):103-9. [Medline].

  88. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005 Jan 25. CD004315. [Medline].

  89. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 1. 67:94-114. [Medline].

  90. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990 Aug. 40(8):1213-8. [Medline].

  91. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology. 1998 May. 50(5):1461-3. [Medline].

  92. Mezaki T, Kaji R, Hamano T, et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatry. 1994 Dec. 57(12):1535-7. [Medline]. [Full Text].

  93. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998 Jan. 64(1):13-7. [Medline]. [Full Text].

  94. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec. 48(12):1253-6. [Medline].

  95. Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology. 1992 Jul. 42(7):1307-10. [Medline].

  96. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil. 1993 Dec. 72(6):364-8. [Medline].

  97. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990 Oct. 28(4):512-5. [Medline].

  98. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000 Jun. 68(6):707-12. [Medline]. [Full Text].

  99. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993 Jul-Aug. 13(4):489-95. [Medline].

  100. Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop. 2000 Jan-Feb. 20(1):108-15. [Medline].

  101. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994 May. 36(5):386-96. [Medline].

  102. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop. 1998 May-Jun. 18(3):304-11. [Medline].

  103. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000 Sep. 137(3):331-7. [Medline].

  104. Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics. 1999 Jun. 30(3):120-4. [Medline].

  105. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002 Oct. 44(10):666-75. [Medline].

  106. Edwards P, Sakzewski L, Copeland L, Gascoigne-Pees L, McLennan K, Thorley M, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics. 2015 Nov. 136 (5):895-904. [Medline].

  107. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug. 69(2):217-21. [Medline]. [Full Text].

  108. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000 Feb. 14(1):5-13. [Medline].

  109. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004 Jul. 85(7):1063-9. [Medline].

  110. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003. 15(4):289-300. [Medline].

  111. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8. 347(6):395-400. [Medline].

  112. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001 Nov. 8(6):559-65. [Medline].

  113. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996 Oct. 47(4):939-44. [Medline].

  114. Pavesi G, Brianti R, Medici D, Mammi P, Mazzucchi A, Mancia D. Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury. J Neurol Neurosurg Psychiatry. 1998 Mar. 64(3):419-20. [Medline]. [Full Text].

  115. Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins--an evidence-based review. Pain Med. 2011 Nov. 12(11):1594-606. [Medline].

  116. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000 Jun 1. 59(11):1403-6. [Medline].

  117. Guo BL, Zheng CX, Sui BD, Li YQ, Wang YY, Yang YL. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013 Sep. 71:134-9. [Medline].

  118. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001 May 22. 56(10):1290-3. [Medline].

  119. Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev. 2011 Jan 19. CD008257. [Medline].

  120. Langevin P, Peloso PM, Lowcock J, Nolan M, Weber J, Gross A, et al. Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Rev. 2011 Jul 6. CD008626. [Medline].

  121. Langevin P, Lowcock J, Weber J, Nolan M, Gross AR, Peloso PM, et al. Botulinum toxin intramuscular injections for neck pain: a systematic review and metaanalysis. J Rheumatol. 2011 Feb. 38(2):203-14. [Medline].

  122. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum Toxin A in Postherpetic Neuralgia: A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial. Clin J Pain. 2013 Jan 30. [Medline].

  123. Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012 Apr. 32(6):443-50. [Medline].

  124. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, et al. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013 Aug 21. 14(1):72. [Medline]. [Full Text].

  125. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009 Apr 28. 72(17):1473-8. [Medline].

  126. Zwart JA, Bovim G, Sand T, Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache. 1994 Sep. 34(8):458-62. [Medline].

  127. Sherman S, Kopecky KK, Brashear A, Lehman GA. Percutaneous celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis. J Clin Gastroenterol. 1995 Jun. 20(4):343-4. [Medline].

  128. Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord. 1996 Jul. 11(4):459. [Medline].

  129. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (Phila Pa 1976). 1998 Aug 1. 23(15):1662-6; discussion 1667. [Medline].

  130. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008 Apr. 26(2):126-35. [Medline].

  131. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998 Jun. 38(6):468-71. [Medline].

  132. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res. 1999 May 26. 4(5):183-6. [Medline].

  133. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg. 1999 Aug. 57(8):916-20; discussion 920-1. [Medline].

  134. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000 Oct. 38(5):466-71. [Medline].

  135. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000 Jun. 40(6):445-50. [Medline].

  136. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. 2000 Apr. 40(4):300-5. [Medline].

  137. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000 Mar. 40(3):231-6. [Medline].

  138. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol. 2000 Feb. 27(2):481-4. [Medline].

  139. Barwood S, Baillieu C, Boyd R, et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol. 2000 Feb. 42(2):116-21. [Medline].

  140. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000 Mar. 85(1-2):101-5. [Medline].

  141. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005 Sep. 53(3):407-15. [Medline].

 
Previous
Next
 
Botulinum toxin structure (schematic diagram).
Proteolytic activity is located at the N-terminal end of the light chain of botulinum toxin type A.
Table 1. Botulinum Toxin Types, Target Sites, Discoverers, and Year Discovered
Type Target Discoverer Year
A SNAP-25 Landman 1904
B VAMP Ermengem 1897
C1 Syntaxin Bengston and Seldon 1922
D VAMP Robinson 1929
E SNAP-25 Gunnison 1936
F VAMP Moller and Scheibel 1960
G VAMP Gimenez and Ciccarelli 1970
Table 2. Studies of Botulinum Toxin in the Treatment of Spasticity in Different Disorders
Clinical Diagnosis Author Study Design
Multiple Sclerosis Benecke



Borg-Stein et al[96]



Snow et al[97]



Hyman et al[98]



Open-label



Open-label



Double-blind, placebo-controlled, randomized, crossover



Double-blind, placebo-controlled, randomized, dose-ranging



Spinal Cord Injury Bohlega et al



Takenaga et al



Open-label



Open-label



Cerebral Palsy Koman et al[99] Koman et al[100]



Cosgrove et al[101]



Chutorian and Root



Chutorian, Root, and the BTA study group



Corry et al[102]



Fehlings et al[103]



Wissel et al[104]



Baker et al[105]



Edwards et al[106]



Open-label



Double-blind, placebo-controlled



Open-label



Open-label



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled



Single-blind, randomized, controlled



Double-blind, randomized, placebo-controlled



Double-blind, randomized, placebo-controlled



Double-blind, randomized, placebo-controlled



Stroke Das and Park Memin et al



Grazko et al



Dengler et al



Jabbari et al



Simpson et al



Bhaktha et al[107]



Smith et al[108]



Childers et al[109]



Pittock et al[110]



Brashear et al[111]



Bakheit et al[112]



Open-label



Open-label



Double-blind, placebo-controlled, crossover



Open-label



Double-blind, placebo-controlled, crossover



Double-blind, placebo-controlled



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Double-blind, placebo-controlled, randomized



Traumatic Brain Injury Yablon et al[113]



Pavesi et al[114]



Open-label



Open-label



Table 3. Studies on the Use of Botulinum Toxin in Pain Management
Author(s) (Year) Clinical Condition Study Type N Results
Zwart et al (1994)[126] Tension headache Open-label 6 Unilateral temporal injection not effective
Sherman et al (1995)[127] Chronic pancreatitis Open-label 7 Not effective
Paulson et al (1996)[128] Fibromyalgia Randomized, controlled 5 Not effective
Wheeler et al (1998)[129] Myofascial pain[130] Randomized, double-blind, controlled 33 No significant difference, second injection effective?
Wheeler (1998)[131] Tension headache Open-label 4 Effective in 4 patients
Schulte-Mattler et al (1999)[132] Tension headache Open-label 9 Effective in 8 of 9 patients
Freund et al (1999)[133] Temporomandibular disorders Open-label 15 Effective
Freund et al (2000)[134] Temporomandibular disorders Open-label 46 Effective
Silberstein et al (2000)[135] Migraine headache Double-blind, vehicle-controlled 123 Effective prophylaxis
Rollnik et al (2000)[136] Tension headache Double-blind, placebo-controlled 21 Not effective
Freund et al (2000)[137] Cervicogenic Headache Randomized, double-blind, placebo-controlled 26 Effective
Freund et al (2000)[138] Whiplash associated with neck pain Randomized, double-blind, placebo-controlled 26 Effective
Barwood et al (2000)[139] Severe postoperative pain and spasm in cerebral palsy Randomized, double-blind, placebo-controlled 16 Effective prophylaxis
Porta (2000)[140] Chronic myofascial pain syndrome Randomized, controlled, comparative 40 BOTOX® better than methylprednisolone
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.